Identification of oxadiazoles as new drug leads for the control of schistosomiasis (original) (raw)

References

  1. Hotez, P.J. et al. Control of neglected tropical diseases. N. Engl. J. Med. 357, 1018–1027 (2007).
    Article CAS Google Scholar
  2. van der Werf, M.J. et al. Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. Acta Trop. 86, 125–139 (2003).
    Article Google Scholar
  3. King, C.H., Dickman, K. & Tisch, D.J. Reassessment of the cost of chronic helminthic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. Lancet 365, 1561–1569 (2005).
    Article Google Scholar
  4. Steinmann, P., Keiser, J., Bos, R., Tanner, M. & Utzinger, J. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect. Dis. 6, 411–425 (2006).
    Article Google Scholar
  5. Fenwick, A. & Webster, J.P. Schistosomiasis: challenges for control, treatment and drug resistance. Curr. Opin. Infect. Dis. 19, 577–582 (2006).
    Article Google Scholar
  6. Herwaldt, B.L., Tao, L.F., van Pelt, W., Tsang, V.C. & Bruce, J.I. Persistence of Schistosoma haematobium infection despite multiple courses of therapy with praziquantel. Clin. Infect. Dis. 20, 309–315 (1995).
    Article CAS Google Scholar
  7. Murray-Smith, S.Q., Scott, B.J., Barton, D.P. & Weinstein, P. A case of refractory schistosomiasis. Med. J. Aust. 165, 458 (1996).
    CAS PubMed Google Scholar
  8. Ismail, M. et al. Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers. Am. J. Trop. Med. Hyg. 60, 932–935 (1999).
    Article CAS Google Scholar
  9. Fallon, P.G. & Doenhoff, M.J. Drug-resistant schistosomiasis: resistance to praziquantel and oxamniquine induced in Schistosoma mansoni in mice is drug specific. Am. J. Trop. Med. Hyg. 51, 83–88 (1994).
    Article CAS Google Scholar
  10. Utzinger, J., Xiao, S.H., Tanner, M. & Keiser, J. Artemisinins for schistosomiasis and beyond. Curr. Opin. Investig. Drugs 8, 105–116 (2007).
    CAS PubMed Google Scholar
  11. Cioli, D., Pica-Mattoccia, L. & Archer, S. Drug resistance in schistosomes. Parasitol. Today 9, 162–166 (1993).
    Article CAS Google Scholar
  12. Abdulla, M.H., Lim, K.C., Sajid, M., McKerrow, J.H. & Caffrey, C.R. Schistosomiasis mansoni: novel chemotherapy using a cysteine protease inhibitor. PLoS Med. 4, e14 (2007).
    Article Google Scholar
  13. Moreira, L.S., Piló-Veloso, D., de Mello, R.T., Coelho, P.M. & Nelson, D.L. A study of the activity of 2-(alkylamino)-1-phenyl-1-ethanethiosulfuric acids against infection by Schistosoma mansoni in a murine model. Trans. R. Soc. Trop. Med. Hyg. 101, 385–390 (2007).
    Article CAS Google Scholar
  14. Townsend, D.M., Tew, K.D. & Tapiero, H. The importance of glutathione in human disease. Biomed. Pharmacother. 57, 145–155 (2003).
    Article CAS Google Scholar
  15. Lillig, C.H. & Holmgren, A. Thioredoxin and related molecules-from biology to health and disease. Antioxid. Redox Signal. 9, 25–47 (2007).
    Article CAS Google Scholar
  16. Alger, H.M. & Williams, D.L. The disulfide redox system of Schistosoma mansoni and the importance of a multifunctional enzyme, thioredoxin glutathione reductase. Mol. Biochem. Parasitol. 121, 129–139 (2002).
    Article CAS Google Scholar
  17. Kuntz, A.N. et al. Thioredoxin glutathione reductase from Schistosoma mansoni: an essential parasite enzyme and a key drug target. PLoS Med. 4, e206 (2007).
    Article Google Scholar
  18. Inglese, J. et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc. Natl. Acad. Sci. USA 103, 11473–11478 (2006).
    Article CAS Google Scholar
  19. Simeonov, A. et al. Quantitative high-throughput screen identifies inhibitors of the Schistosoma mansoni redox cascade. PLoS Negl. Trop. Dis 2, e127 (2008).
    Article Google Scholar
  20. Ramirez, B. et al. Schistosomes: challenges in compound screening. Expert Opin. Drug Discov. 2 (Suppl. 1), S53–S61 (2007).
    Article CAS Google Scholar
  21. Feelisch, M., Schönafinger, K. & Noack, E. Thiol-mediated generation of nitric oxide accounts for the vasodilator action of furoxans. Biochem. Pharmacol. 44, 1149–1157 (1992).
    Article CAS Google Scholar
  22. Akaike, T. et al. Antagonistic action of imidazolineoxyl N-oxides against endothelium-derived relaxing factor/NO through a radical reaction. Biochemistry 32, 827–832 (1993).
    Article CAS Google Scholar
  23. Trouiller, P. et al. Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet 359, 2188–2194 (2002).
    Article Google Scholar
  24. Austin, C.P., Brady, L.S., Insel, T.R. & Collins, F.S. NIH Molecular Libraries Initiative. Science 306, 1138–1139 (2004).
    Article CAS Google Scholar
  25. Cerecetto, H. & Porcal, W. Pharmacological properties of furoxans and benzofuroxans: recent developments. Mini Rev. Med. Chem. 5, 57–71 (2005).
    Article CAS Google Scholar
  26. James, S.L. & Glaven, J. Macrophage cytotoxicity against schistosomula of Schistosoma mansoni involves arginine-dependent production of reactive nitrogen intermediates. J. Immunol. 143, 4208–4212 (1989).
    CAS PubMed Google Scholar
  27. Medana, C. et al. Furoxans as nitric oxide donors. 4-Phenyl-3-furoxancarbonitrile: thiol-mediated nitric oxide release and biological evaluation. J. Med. Chem. 37, 4412–4416 (1994).
    Article CAS Google Scholar
  28. Nordberg, J. & Arner, E.S. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radic. Biol. Med. 31, 1287–1312 (2001).
    Article CAS Google Scholar
  29. Nwaka, S. & Hudson, A. Innovative lead discovery strategies for tropical diseases. Nat. Rev. Drug Discov. 5, 941–955 (2006).
    Article CAS Google Scholar
  30. Sabah, A.A., Fletcher, C., Webbe, G. & Doenhoff, M.J. Schistosoma mansoni: chemotherapy of infections of different ages. Exp. Parasitol. 61, 294–303 (1986).
    Article CAS Google Scholar
  31. Shuhua, X., Chollet, J., Weiss, N.A., Bergquist, R.N. & Tanner, M. Preventive effect of artemether in experimental animals infected with Schistosoma mansoni. Parasitol. Int. 49, 19–24 (2000).
    Article CAS Google Scholar
  32. Lewis, F. Schistosomiasis. in Current Protocols in Immunology (eds. Coligan, J.E., Kruisbeek, A.M., Margulies, D.H., Shevach, E.M. & Strober, W.) 19.1.1–19.1.28 (John Wiley & Sons, New York, 1998).
    Google Scholar
  33. Bergmeyer, H.U. & Bernt, E. Lactate dehydrogenase. in Methods of Enzymatic Analysis Vol. 2 (ed. Bergmeyer, H.U.) 574–548 (Academic Press, New York, 1974).
    Chapter Google Scholar
  34. Aguirre, G. et al. Furoxan derivatives as cytotoxic agents: preliminary in vivo antitumoral activity studies. Pharmazie 61, 54–59 (2006).
    CAS PubMed Google Scholar
  35. Skehan, P. et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 82, 107–112 (1990).
    Article Google Scholar
  36. Nims, R.W. et al. Colorimetric methods for the determination of nitric oxide concentration in neutral aqueous solutions. Methods 7, 48–54 (1995).
    Article CAS Google Scholar

Download references